

Laboratory Bulletin for Clinicians

March 2, 2020

Starting immediately, the Ministry of Health (Ministry) has approved the expanded use of fecal calprotectin (FC) testing to include all patients diagnosed with inflammatory bowel disease (IBD) in BC.

FC is a biomarker of intestinal inflammation and is a non-invasive means of monitoring IBD activity which includes response to therapy, and disease relapse. LifeLabs currently provides FC testing for the province. Additional testing sites are anticipated in the coming months.

Clinicians MUST indicate IBD in the diagnosis box on the requisition to ensure that the test request is accepted by the laboratory.

Who should be tested?

FC can be requested for any patient diagnosed with IBD to:

1. Confirm IBD response to treatment
2. Confirm remission of IBD activity
3. Assist in the identification of IBD relapse

How to interpret the results?

FC results vary by methodology. Refer to the reference range accompanying the test result and any appended comments to ensure appropriate interpretation.